Cell-based Therapy for the Treatment of Kidney Disease (CTKD)

Mass General Brigham

Status and phase: Not yet enrolling; Early Phase 1

Conditions: Kidney Diseases

Treatments: Biological: endothelial progenitor cell

Study type: Interventional

Funder types: Other

Identifiers

NCT04187625

2019P003586

Details and patient eligibility

About

Endothelial progenitor cells derived from and delivered to the renal vasculature may be stimulated to initiate differentiation programs during episodes of injury. It is hypothesized that endothelial progenitor cells from the kidney can transition to a phenotype that promotes endothelial repair.

Full description

This is an interventional study involving patients that have a diagnosis of chronic kidney disease. Patients will have at least stage 3 chronic kidney disease stage or greater. Kidney-derived endothelial progenitor cells will have been obtained using associated protocols that are currently approved by the Partners Human Research Committee.

Enrollment: 10 estimated patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Enrolled patients will have endothelial progenitor cells previously acquired.

Exclusion criteria

• Patients without previously acquired endothelial progenitor cells will be excluded.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

Intervention

Experimental group

Description:

Patients will be given autologous endothelial progenitor cells

Treatment:

Biological: endothelial progenitor cell